chemoprevention of colonic aberrant crypt foci by Schiff based zinc (II) complex in azoxymethane-induced colorectal cancer in rodents
Mahmood Ameen Abdulla
mahmood.ameen@cihanuniversity.edu.iq
Abstract- Background: Based on the potential of Schiff base compounds to act as sources for the development of cancer chemotherapeutic agents, this in vivo study was performed to investigate the inhibitory properties of the synthetic Schiff base compound Zinc (II) on colonic aberrant crypt foci (ACF).
Methodology:
This study involved five groups of male rats. The negative control group was injected with normal saline once a week for 2 weeks and fed 10% Tween 20 for 8 weeks, the cancer control group was subcutaneously injected with 15 mg/kg azoxymethane once per week for two consecutive weeks, the positive control group was injected with 15 mg/kg azoxymethane once per week for two consecutive weeks and 35 mg/kg 5-fluorouracil (injected IP) for 4 weeks, and the experimental groups were first injected with 15 mg/kg azoxymethane once per week for two consecutive weeks and then fed 25 or 50 mg/kg of the Schiff base compound once a day for 8 weeks Application of the Schiff base compound suppressed total colonic ACF formation by up to 72% to 74% when compared with the cancer control group..
Histologically, all treatment groups exhibited significant decreases in dysplasia compared to the cancer control group.
Immunohistochemical staining demonstrated down-regulation of the PCNA protein. and up-regulation of Bax expression compared with the AOM control group.
Conclusion:
The current study demonstrated that the Schiff base zinc (II)) compound has promising chemoprotective activities that are evidenced by significant decreases in the numbers of ACFs in azoxymethane-induced colon cancer.
Keywords- Schiff base zinc (II), ACF, AOM, Histology, IHC
Date: 6/4/2021
Place: Department of General Biology